All In Biotech

Drug Trial Radar · NCT06855771

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of Navlimetostat (BMS-986504) Monotherapy and in Combination With Izalontamab Brengitecan in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss After Progression on Prior Therapies

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

182

Planned (sponsor's estimate)

Start

Sep 9, 2025

Primary completion

Dec 29, 2028

Study completion Dec 30, 2031

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Mar 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion or MTAP loss after progression on prior therapies.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • BMS-986504Drug

    Specified dose on specified days

  • Izalontamab BrengitecanDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants who achieve Objective Response (OR) utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Up to 3 years after the last participant's last dose of study treatment
  2. Number of participants with adverse events meeting protocol defined dose limiting toxicities (DLTs) criteriaTime frame: Up to 28 days after the last dose of study treatment
  3. Number of participants with adverse events (AE)Time frame: Up to 28 days after the last dose of study treatment
  4. Number of participants with Serious AEs (SAEs)Time frame: Up to 28 days after the last dose of study treatment
  5. Number of participants with treatment related AEsTime frame: Up to 28 days after the last dose of study treatment
  6. Number of participants with treatment related SAEsTime frame: Up to 28 days after the last dose of study treatment
  7. Number of participants with AEs leading to study treatment discontinuationTime frame: Up to 28 days after the last dose of study treatment
  8. Number of participants with AEs leading to deathTime frame: Up to 28 days after the last dose of study treatment
  9. Number of participants with laboratory abnormalitiesTime frame: Up to 28 days after the last dose of study treatment

Locations

67 sites in 12 countries. Site status is shown where the registry gives one.

  • Local Institution - 0088

    Anchorage, Alaska · Completed

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Gabrail Cancer Center

    Canton, Ohio · Recruiting

  • Providence Portland Medical Center

    Portland, Oregon · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • Fred Hutchison Cancer Center

    Seattle, Washington · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • GenesisCare - Campbelltown

    Campbelltown, New South Wales, Australia · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • Local Institution - 0097

    Adelaide, South Australia, Australia · Completed

  • Beijing Chest Hospital,Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Recruiting

  • LinYi Cancer Hospital

    Linyi, Shandong, China · Recruiting

  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Taizhou Hospital of Zhejiang Province

    Linhai, Zhejiang, China · Recruiting

  • Hopitaux Universitaires Paris Centre-Hopital Cochin

    Paris, France · Recruiting

  • Institut Curie

    Paris, France · Recruiting

  • Hôpital Tenon

    Paris, France · Recruiting

  • Groupe hospitalier Paris saint Joseph

    Paris, Île-de-France Region, France · Recruiting

  • Chu Grenoble Alpes

    La Tronche, Isère, France · Recruiting

  • Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes

    Saint-Herblain, Loire-Atlantique, France · Recruiting

  • Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois

    Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France · Recruiting

  • Hospices Civils de Lyon - Hopital Louis Pradel

    Bron, Rhône, France · Recruiting

  • Universitaetsklinikum Koeln

    Cologne, Germany · Recruiting

  • Universitaetsklinikum Wuerzburg

    Würzburg, Germany · Recruiting

  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen

    München, Bavaria, Germany · Recruiting

  • Universitätsklinikum Frankfurt Goethe-Universität

    Frankfurt am Main, Hesse, Germany · Recruiting

  • Krankenhaus Martha-Maria Halle-Dölau

    Halle, Saxony-Anhalt, Germany · Recruiting

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola

    Bologna, Italy · Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy · Recruiting

  • AOU della Campania Luigi Vanvitelli

    Naples, Campania, Italy · Recruiting

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale

    Naples, Campania, Italy · Recruiting

  • Fondazione IRCCS San Gerardo dei Tintori

    Monza, Lombardy, Italy · Recruiting

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.